The MTTP inhibitor (lomitapide) is also approved for the treatment of inherited hyperlipidemias like homozygous familial hypercholesterolemia and familial chylomicronemia syndrome, but its usage is associated with severe side effects and therefore is not recommended for the treatment of obesity (Ko et al, 2020). Here, MT-TP is linked to obesity due to melanocortin 4 receptor deficiency.